Cannabis News

Massachusetts Governor Signs Bill Doubling Legal Marijuana Possession Limit And Revising Industry Rules

Published

2 months ago

April 19, 2026

admin

The governor of Massachusetts has signed a bill double the legal limit for adult marijuana possession and revise the regulatory framework for the state’s adult cannabis market.

Gov. Maura Healey (D) approved the legislation Sunday, about a week and a half after lawmakers sent it to her desk in unanimous House and Senate votes.

“The cannabis industry is an important part of the Massachusetts economy: it supports jobs and local businesses and generates revenue for cities and towns,” Healey said in a press release. “It is important that we are doing everything we can to ensure that this industry is set up to succeed and remain competitive in this growing market. I am grateful to the Legislature for their leadership on this critical reform project.”

A bicameral conference committee spent months working on provisions of the legislation after the two chambers passed different versions last year, and the committee approved the compromise approach on Monday.

“With the governor’s signature today, our legislature takes an important step toward making the cannabis industry here in Massachusetts more profitable, profitable and competitive for business owners and consumers,” said Sen. Adam Gómez (D), who chaired the bicameral panel. “This legislation strengthens the Cannabis Regulatory Commission’s oversight by making smart updates that help small businesses, improve accountability, and ensure consumers can safely and legally access cannabis.”

“By clarifying shipping and advertising rules, increasing accounts receivable transparency, increasing purchase amounts and modernizing licensing limits, we’re building a more stable and fairer cannabis market for our state and I’m proud of our body for prioritizing reform this session,” he said.

Rep. Daniel M. Donahue (D), who also chaired the conference committee and co-chairs the Joint Committee on Cannabis Policy with Gómez, said he is “delighted” that the legislation became law.

“These reforms represent a new commitment to ensuring a safe, equitable and prosperous future for the Commonwealth’s legalized cannabis industry,” he said. “I look forward to working with the administration through their implementation.”

Among the revisions to the state’s cannabis law is a section that increases the personal possession limit of marijuana from one ounce to two. Colorado enacted the same reform in 2021 after the state’s cannabis market matured.

H.5350 reduces the size of the Cannabis Control Commission (CCC) and overhauls the organization, while also updating the limits on marijuana business licenses.

—
It’s Marijuana Time tracking hundreds of cannabis, psychedelic and drug policy bills in state legislatures and Congress this year. Patreon supporters by pledging at least $25/month, you’ll get access to our interactive maps, charts, and audio calendars so you never miss a development.

Learn more about our marijuana bill tracking and become a Patreon supporter to gain access
—

According to the versions of both chambers invoiceThe CCC would consist of three members instead of the current five. Conference committee the report it takes provisions of the House measure that has now become law that would allow the governor to make all appointments, with the Senate approach giving the attorney general one of the appointments. According to the previous law, the treasurer also had a role in appointing committee members, but this will no longer be the case.

The proposal calls for one member of the CCC to have a background in social justice, while the other two commissioners have a background in public health, public safety, social justice, consumer regulation or the production and distribution of cannabis.

The new law also increases the number of licenses a single entity can hold from three to six, and also raises from 10 percent to 20 percent the threshold for how much of a company’s equity is considered property to count toward the license cap. It also removes a current requirement that medical cannabis operators be vertically integrated to simultaneously cultivate, manufacture and sell marijuana.

It also empowers regulators to choose dispensaries to advertise sales, discounts and customer loyalty programs at retail locations and via email, and specifies that marijuana dispensary operators can deliver to any municipality unless local officials proactively ban cannabis businesses and stop delivery.

The measure creates a new portal for reporting illegal behavior and directs regulators to create a list of cannabis companies that have not paid their debts to other operators for more than 60 days and prevents regulators from doing business with other operators until the debts are settled.

The legislation also requires regulators to study and report on hemp-derived products, the public health impacts of cannabis, tax policy and workplace safety regulations.

Before the governor signed the bill, the CCC published guidance on the immediate effect of the new law.

Attention licensees: The commission has released a bulletin on the immediate effects of new cannabis legislation on the Governor’s desk, slated to become law this Sunday. Learn more: https://t.co/rvLWIp4LkR

— Massachusetts Cannabis Control Board (@MA_Cannabis) April 17, 2026

After signing the bill on Sunday, CCC Executive Director Travis Ahern he said “During this transition, the organization will remain focused on its primary mission of regulating a safe and fair cannabis industry for Massachusetts consumers, patients, employers and taxpayers.”

Cannabis regulation reform has come into effect after state marijuana businesses filed a lawsuit aimed at blocking it. initiative to roll back the legalization law approved by state voters from reaching the November vote.

If approved, the state would not return to general prohibition; rather, it would repeal the commercial recreational sales and home cultivation components of the law, while allowing adults 21 and older to possess one ounce of cannabis for personal use.

Possession of more than one ounce but less than two ounces would effectively be decriminalized, with violators facing a $100 fine. Adults can also continue to gift cannabis to each other without payment. The sale of medical marijuana would be legal.

The measure is before the legislature after supporters provided an initial round of signatures last year, and lawmakers have until May 5 to act on the proposal. If they decide not to pass it in the legislature, the campaign would have to go through another round of petitions and get at least 12,429 certified signatures by July 1 to get on the November ballot.

The promoters faced skeptical questions from lawmakers at a hearing of the Joint Committee on Initiative Petitions last month, with several. raising concerns about the motivations behind the anti-marijuana measure and the consequences for consumers and companies.

A Bay State Poll by the University of Hampshire State Opinion Project found that A majority of Massachusetts adults oppose the initiative to repeal the sale and cultivation of marijuana.

Meanwhile, in November, the legislature’s Joint Committee on Cannabis Policy advanced a bill that would have required a study. legal barriers facing first responders who want to use marijuana in compliance with state law.

Regulators should also examine marijuana’s effectiveness in the treatment of anxiety, depression and post-traumatic stress disorder (PTSD). In addition, police and first responders in other jurisdictions will review laws and policies regarding the use of cannabis and “any other matter deemed relevant by the commission.”

The bill was reported when lawmakers in another committee passed separate legislation employment protection for people who use marijuana. Another panel advanced a a bill similar to the employment protections for cannabis in September

Meanwhile, the head of Massachusetts’ marijuana regulatory agency recently suggested measures to effectively recriminalize the sale of recreational cannabis. dangerous tax revenues being used to support substance abuse treatment efforts and other public programs.

To that point, Massachusetts recently achieved another marijuana milestone, officials announced in February that the state has. Over $9 billion in adult cannabis purchases since market launch in 2018.

A report by the Cannabis Control Commission (CCC) found that legalization is achieving one of its main goals: stopping the illegal sale of cannabis as adults move into the regulated market. It shows that among adults who used marijuana in the past year, a staggering 84 percent said they got their cannabis from a licensed source.

Massachusetts lawmakers recently joined a bicameral conference committee to hammer out a deal. double the legal limit for possession of marijuana for adults and reviewing the regulatory framework for the state’s adult cannabis market.

In December, state regulators, too established rules for the halls of social consumption of marijuana.

CCC has recently launched a targeted online platform helping people find work, on-the-job training and networking opportunities in the state’s legal cannabis industry.

Separately, members of parliament are advancing the legislation establishing pilot programs for the regulated therapeutic use of psychedelics.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Cannabis News

Entourage Health, formerly WeedMD, enters creditor protection

Published

6 hours ago

June 30, 2026

admin

Entourage Health Corp. has entered creditor protection. The company and six related entities filed on June 17 under the Companies’ Creditors’ Arrangement Act owed approximately $240.1 million to the sole affiliate of the LiUNA Pension Fund, its owner, its secured creditor and the lender that is now funding the money (First Report pp. 3-6-9

That affiliate, 2437653 Ontario Inc. No. 1 company, Entourage, secured a 2024 deal that took the former WeedMD private and off the TSX Venture Exchange (December 2024 PR). Shareholders were paid half a Canadian cent per share, or C$0.005, and the board recommended a sale in December 2024 (December 2024 PR).

Jason Alexander, head of the special committee of independent directors, recommended to shareholders. “The transaction ensures that shareholders will receive immediate tangible value while positioning the Company for future growth and flexibility,” Alexander said (December 2024 PR). The company took on $167.6 million in debt in that sale, having already breached the covenant with the same guarantee (December 2024 PR). Eighteen months later that debt was $240.1 million when it was filed, and the growth promised by the sale is a settlement (First Report 6-18 p.

Adult use is off, medical is still running
The leisure business is closing, not saving. Entourage laid off about 53 workers in early June before the order, and 22 remain (First Report p. 6 Adult use inventory is being cleared, finished products are shipped to provincial distributors, and flowers are sold in bulk to the market to other licensed growers (First Report p. 12 Color Cannabis, Dime Bag and Saturday Cannabis are the brands going down with it (First Report p. 5

What remains open is the doctor’s arm as the exclusive supplier of cannabis under the Starseed brand to local residents of the Workers International Union of North America (First Report p. 5 The pension fund that funds the procedure is tied to the same union that the medical brand serves, and the part of Entourage that serves union members is the part that is kept alive while the rest is sold for parts.

At the end of July the money runs out with no new money (First Report p. 11 The money comes again from the pension fund affiliate, a $1.1 million debtor-in-possession facility at 5% per annum, no commitment fee, no exit fee (First Report pp. 10-11). The monitor, Ernst & Young, checked terms against other DIP loans in the cannabis sector from January 2024 and concluded that a third-party lender would not lend on better terms given the state of the business (First Report p. 11 The lender, which already owed $240 million, is the only one willing to advance another million to keep the lights on through the sale.

Health Canada is the largest unsecured creditor, owed $494,505, ahead of all suppliers and competitors on the company’s books (List of Creditors p. 1 Supreme Cannabis is owed $262,133, medical platform HelloMD is owed $169,564, the Town of Aylmer is owed $144,815, the Independent Retail Cannabis Board is owed $137,098 and High Tide is owed $124,583 (List of Creditors p. 1 Unsecured claims total $3,288,333 in more than 100 names, many of which have yet-to-be-determined amounts by medical clinics (List of Creditors 1-5 p. Against $240 million guaranteed, none of them will see much.

In the June 29 return, the lender asks the judge to extend the stay until August 28, approve the DIP facility, and double the Administrative and Directors fees to $500,000 each (First Report 4-8-12. p. The directorship is rising as directors face payroll, holiday pay and excise duties over a longer period of time, and the company’s directors and officers insurance expires at the start of July (First Report p. 12

The sales process starts on the same day, based on a marketing effort that started around May and was presented before the deal that sparked interest but no one could make a deal (First Report p. 13 Insiders and affiliates have until July 6th to say they intend to bid, the bid deadline is July 30th, the successful bid must be received by August 7th, and the outside deadline is August 28th (First Report p. 15 The affiliate of the pension fund has written to the Monitor that it will not make an offer (First Report p. 16), and any other affiliate that does so must be removed from the process (First Report p. 16 The settlement request for non-cannabis equipment and the sale of the Aylmer facility, a 26,000-square-foot extraction and processing facility that has been the company’s production base at 250 Elm St.

the source

For more information:
Neighborhood Health
1.844.933.3636
(email protected)
entouragehealthcorp.com

Cannabis News

DEA And FDA Highlight How Marijuana Is Safer Than Alcohol And Opioids During Rescheduling Hearing’s Opening Day

Published

6 hours ago

June 30, 2026

admin

Attorneys for the Drug Enforcement Administration (DEA) on Monday highlighted testimony about the medical benefits of marijuana and its relative safety compared to other substances such as alcohol and opioids in the opening day of a hearing. The Trump administration’s cannabis rescheduling proposal.

Marijuana Moment spoke with several people in the audience for Monday’s hearing to find out how the testimony is going, despite the proceedings not being broadcast live to the public at the request of one congressman and others.

According to those sources, DEA attorney James J Schwartz stated that the government is the proponent of the proposed rule to formally move cannabis from Schedule I to Schedule III of the Controlled Substances Act (CSA), stating that the hearing is “not about the recreational use of marijuana” and “about regulation, not about legalization.”

“The government has presented no evidence to suggest that marijuana is not dangerous. All controlled substances are dangerous,
he said “However, controlled substances must be evaluated against the risks they pose, balanced against the medical benefits they provide.”

Dominic Chiapperino, director of the Food and Drug Administration’s Center for Controlled Drug Evaluation and Research and one of two DEA witnesses, testified about how federal health officials formed their recommendation to reschedule cannabis.

Opponents of the reform have used a new two-part test that they argue is a bad departure from a previous analysis, although a DEA lawyer said the hearing is not about that issue, and Chiapperino said the new test is now considered “every time” a new analysis is done on a drug.

The FDA official said the agency compared marijuana to alcohol, opioids and other substances in its scheduling analysis, and found that marijuana’s daily harms were lower than all or most of those comparators.

Cannabis is associated with fewer overdose deaths than comparable substances, Chiapperino said, and when reports of cases involving deaths mention marijuana, the deaths are often attributed to secondary incidents such as accidents or self-inflicted harm. Marijuana’s potential for overdose deaths is “much lower” than other Schedule I drugs and Schedule II drugs. Rather than opioids, the FDA official said.

As for withdrawal in regular users, Chiapperino testified that cannabis has symptoms similar to tobacco, including irritability, but alcohol has “more of a withdrawal syndrome,” which can include seizure and death.

Also on Monday, the lawyers of some of the parties against the reorganization had the opportunity to cross Chiapperino.

Kevin Sabet, president and CEO of the prohibitionist organization Smart Approaches to Marijuana, who was also invited to attend the hearing, said in a video posted on social media that it is “surreal” to see the government arguing that cannabis’s medical uses and relatively minor harms are “just lying through their teeth.”

The DEA “is in a very awkward position to argue the opposite of what it’s been arguing for the last 50 years, the opposite of what the science says, the opposite of what the evidence is,” he said, “which is, of course, to argue against the government that marijuana is more harmful than we thought, not less harmful.”

In short, the government has so far been repeating the inappropriate comparison of marijuana to alcohol, heroin, and other opioids. And duplicating the unprecedented new two-part test for medical use now accepted, which overturns a century of work in this medical…

— Smart Approaches to Marijuana (@learnaboutsam) June 29, 2026

On Tuesday, opponents of the review will have an opportunity to cross-examine the FDA official, and the government’s second witness, Corey Burchman, a doctor from New Hampshire, will begin his testimony. The DEA announced in a filing last week that it will do so Testify on “How Medical Marijuana Provides Medical Benefit to Pain Patients.”

On Monday, a DEA attorney said Burchman would “describe the real-world impacts of treating pain with marijuana instead of opioids” based on his experience with both and discuss how he has “personally transitioned patients from opioids to marijuana for their pain.”

The witness will also testify about the differences between cannabis and opioids in terms of withdrawal and overdose, he said.

Before the hearing began, marijuana reform activists rallied They held a press conference outside DEA headquarters to highlight how they feel of the process – criticizing the fact that supporters of the reform were not invited to participate and that the proceedings are not reproduced live, despite the “transparency” oath of the officials.

DEA Administrator Terrance Cole only organizations and individuals opposed to marijuana reform have been invited to the hearing as a designated participant – telling followers that they do not meet the definition of “interested person” to participate because they are not “affected or prejudiced by any rule or proposed rule that may be issued.”

last week, Marihuana Moments sent petitions to DEA Chief Administrative Law Judge Derek Julius and DEA Administrator Cole asking for them reverse the decision to ban the public from tuning into the cannabis hearing via live stream. A Congressmen and other journalists later joined that request.

—
Marijuana Moment’s journalism is made possible by readers like you, who value this work enough to support us Patreon Monthly Pledges. If you rely on our reports to stay informed of important developments in cannabis, please help us do this becoming a permanent subscriber today.

Backed by us at the $25/month level, you’ll have access to our Bill Tracker so you don’t miss any important marijuana legislation in your state.
—

The opponents who are participating in the hearing submitted statements last week anticipate the anti-marijuana arguments they intend to make during the procedure.

The hearing it will end before July 15.

Acting Attorney General Todd Blanche in April He issued an order that immediately reclassified the state’s licensed medical cannabisas well as marijuana products approved by the Food and Drug Administration (FDA) under Schedule I through Schedule III of the Controlled Substances Act (CSA).

According to a separate order signed by the acting attorney general, the upcoming hearing will include Class III marijuana.

Preliminary hearing process on the marijuana redistricting process initiated by the Biden administration It was halted last year amid allegations of improper communications and witness selection.

the current The marijuana redistricting process is being challenged in several ways which have been upheld by a federal Court of Appeals. those pieces of State attorneys general have filed lawsuits against cannabis reform, Opponents of marijuana legalization and a a cannabis-based biopharmaceutical corporation.

Meanwhile, the reorganization of state-licensed medical cannabis is already having a major impact.

The Congressional Research Service published a report on the current rescheduling of cannabis Certified patients with medical marijuana from state licensed dispensaries are now eligible for Class III. “The order appears to allow end users to use marijuana medically without a CSA prescription,” he says.

The Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF) has published a Draft update to a gun purchase form to recognize the legal status of medical marijuana in the reprogramming. The revised section of the question states that only the “recreational use or possession of marijuana” is federally prohibited, omitting the prior form’s mention of medical cannabis.

The US Treasury and Internal Revenue Service (IRS) said they plan to issued new tax guidelines for the marijuana industry after reprogramming. The reform will benefit state-licensed marijuana businesses by allowing them to take federal tax deductions that are currently prohibited under IRS Code Section III, known as Section 280E.

Even the DEA, which has long opposed cannabis legalization and accused the Biden administration of stalling the initiative in the reorganization process, has done so. It launched a registration process for legal marijuana businesses in the state to take advantage of the federal benefits that come with the reform.

The Department of Transport, on the other hand, issued guidelines stating this use Legal medical cannabis in the state is still no excuse for truck drivers to test positive for drugspilots and other safety-sensitive personnel.

A congressional committee recently Federal officials voted to block further steps to reschedule cannabishowever lawmakers from both parties told Marihuana Moment they don’t think that provision will be enacted become law

user photo Carlos Gracia.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Cannabis News

cbdMD welcomes White House call for fair treatment of hemp-derived products

Published

1 day ago

June 29, 2026

admin

cbdMD welcomes the Administration’s call for Congress to ensure fair treatment of hemp-derived products under federal law and calls for immediate action to revise hemp regulations to ensure fair treatment of hemp products under federal law.

In a letter to congressional leadership this week, the White House Office of Management and Budget identified hemp reform as a priority strongly supported by the Administration. The petition calls on Congress to ensure fair treatment of hemp-derived products by maintaining access to appropriate full-spectrum CBD products, and by maintaining Congress’ intent to reduce products that pose health risks. The administration also urged Congress to pass a responsible federal framework or at least extend the current implementation period to give lawmakers time to get policy right. The request builds on the president’s previous public statements urging lawmakers to protect access to full-spectrum CBD products that millions of Americans rely on.

“We are encouraged to see the administration so clearly championing the responsible, scientific hemp products that consumers depend on every day,” said Ronan Kennedy, CEO of cbdMD. “cbdMD has always believed that the future of this category is built on quality, transparency, and clear rules that separate them from bad actors. A federal framework that protects consumer access, promotes safety, and provides certainty to companies that provide certainty is what this industry and the people it serves deserve. We applaud the policymakers who are working to achieve this outcome.”

“We believe CbdMD is purpose-built for this next phase of the market,” added Kennedy. “Our focus remains on serving our customers with reliable and effective products, supporting responsible regulation and building long-term value for our shareholders as the category continues to evolve. Along the way, we will continue to evaluate the opportunities this evolving environment holds.”

For more information:
cbdMD
cbdmd.com/